Selection criteria for antifungals: the right patients and the right reasons

被引：6

作者：

Chandrasekar, Pranatharthi ^{[1
]}

机构：

[1] Wayne State Univ, Harper Hosp, Sch Med, Div Infect Dis, Detroit, MI 48201 USA

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2006年 / 27卷

关键词：

invasive fungal infections; antifungal therapy; combination treatment; aspergillosis; candidiasis; zygomycosis;

D O I：

10.1016/j.ijantimicag.2006.03.014

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The increasing number of new antifungal agents and their range of licensed indications mean that clinicians now have several pharmacological options for combating fungal infections. This paper briefly reviews the current available agents and seeks to introduce evidence that will help ensure optimal treatment for each type of fungal infection. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：S17 / S20

页数：4

共 15 条

[1]

GREENBERG RN, 2003, P 43 INT C ANT AG CH

[2] Trends in the postmortem epidemiology of invasive fungal infections at a university hospital [J].

Groll, AH ;

Shah, PM ;

Mentzel, C ;

Schneider, M ;

JustNuebling, G ;

Huebner, K .

JOURNAL OF INFECTION, 1996, 33 (01) :23-32

[3] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[4] Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole [J].

Imhof, A ;

Balajee, SA ;

Fredricks, DN ;

Englund, JA ;

Marr, KA .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) :743-746

[5] Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial [J].

Kullberg, BJ ;

Sobel, JD ;

Ruhnke, M ;

Pappas, PG ;

Viscoli, C ;

Rex, JH ;

Cleary, JD ;

Rubinstein, E ;

Church, LWP ;

Brown, JM ;

Schlamm, HT ;

Oborska, IT ;

Hilton, F ;

Hodges, MR .

LANCET, 2005, 366 (9495) :1435-1442

[6]

Larkin JA, 2003, INFECT MED, V20, P201

[7] Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants [J].

Marty, FM ;

Cosimi, LA ;

Baden, LR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (09) :950-952

[8] Comparison of caspofungin and amphotericin B for invasive candidiasis. [J].

Mora-Duarte, J ;

Betts, R ;

Rotstein, C ;

Colombo, AL ;

Thompson-Moya, L ;

Smietana, J ;

Lupinacci, R ;

Sable, C ;

Kartsonis, N ;

Perfect, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2020-2029

[9]

Ostrosky-Zeichner L, 2003, CLIN INFECT DIS, V37, P415, DOI 10.1086/376634

[10] Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex [J].

Perfect, JR .

CLINICAL INFECTIOUS DISEASES, 2005, 40 :S401-S408

← 1 2 →